AP3642A - Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof - Google Patents

Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof

Info

Publication number
AP3642A
AP3642A AP2008004609A AP2008004609A AP3642A AP 3642 A AP3642 A AP 3642A AP 2008004609 A AP2008004609 A AP 2008004609A AP 2008004609 A AP2008004609 A AP 2008004609A AP 3642 A AP3642 A AP 3642A
Authority
AP
ARIPO
Prior art keywords
hiv
regulatory
peptides
utilization
compositions
Prior art date
Application number
AP2008004609A
Other languages
English (en)
Other versions
AP2008004609A0 (en
Inventor
Gregory Alan Stoloff
Wilson Romero Caparros-Wanderley
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0604920A external-priority patent/GB0604920D0/en
Priority claimed from GB0614260A external-priority patent/GB0614260D0/en
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of AP2008004609A0 publication Critical patent/AP2008004609A0/xx
Application granted granted Critical
Publication of AP3642A publication Critical patent/AP3642A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AP2008004609A 2006-03-10 2007-03-09 Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof AP3642A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0604920A GB0604920D0 (en) 2006-03-10 2006-03-10 Peptide sequences and compositions
GB0614260A GB0614260D0 (en) 2006-07-18 2006-07-18 Peptide sequences and compositions
PCT/GB2007/000812 WO2007104932A2 (en) 2006-03-10 2007-03-09 Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof

Publications (2)

Publication Number Publication Date
AP2008004609A0 AP2008004609A0 (en) 2008-10-31
AP3642A true AP3642A (en) 2016-03-16

Family

ID=38232608

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2015008680A AP2015008680A0 (en) 2006-03-10 2007-03-09 Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof
AP2008004609A AP3642A (en) 2006-03-10 2007-03-09 Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AP2015008680A AP2015008680A0 (en) 2006-03-10 2007-03-09 Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof

Country Status (20)

Country Link
US (4) US20100055119A1 (pl)
EP (2) EP2392587B1 (pl)
JP (3) JP2009529570A (pl)
KR (1) KR20080106467A (pl)
CN (2) CN102443052B (pl)
AP (2) AP2015008680A0 (pl)
AU (1) AU2007226430B2 (pl)
BR (1) BRPI0708708A2 (pl)
CA (1) CA2645342A1 (pl)
DK (2) DK2392587T3 (pl)
EA (1) EA019733B1 (pl)
ES (2) ES2573105T3 (pl)
IL (2) IL193965A0 (pl)
MX (1) MX2008011520A (pl)
NO (1) NO20083576L (pl)
NZ (1) NZ570708A (pl)
PL (1) PL2392587T3 (pl)
SG (1) SG170092A1 (pl)
UA (1) UA97800C2 (pl)
WO (1) WO2007104932A2 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
CA2932788A1 (en) 2013-12-08 2015-06-11 Peptcell Limited Hiv antigens and antibodies and compositions, methods and uses thereof
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000049038A2 (de) * 1999-02-19 2000-08-24 Ulrich Schubert Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung
WO2003015702A2 (en) * 2001-08-16 2003-02-27 The General Hospital Corporation Epitopes of human immunodeficiency virus-1

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (en) 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
DE4141970C2 (de) 1991-12-16 1998-02-19 Charite Med Fakultaet Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung
JPH08504837A (ja) 1993-10-14 1996-05-28 生化学工業株式会社 新規ポリペプチドおよびこれから調製される抗ｈｉｖ剤
AU685521B2 (en) 1993-10-19 1998-01-22 Ajinomoto Co., Inc. Peptide capable of inducing immune response against HIV and aids preventive or remedy containing the peptide
US5843724A (en) * 1995-04-27 1998-12-01 Rutgers University Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
AU7689798A (en) * 1997-05-20 1998-12-11 St. Luke's-Roosevelt Hospital Vif-derived hiv protease inhibitors
AU752725B2 (en) 1997-09-18 2002-09-26 Trustees Of The University Of Pennsylvania, The Attenuated vif DNA immunization cassettes for genetic vaccines
US6228128B1 (en) 1997-11-10 2001-05-08 Charlotte Johansen Antimicrobial activity of laccases
US20020182222A1 (en) * 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
US20030180314A1 (en) 1998-07-10 2003-09-25 Degroot Anne Immunogenic, cross-clade, HIV peptides
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
AU1075001A (en) * 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
EP1250351B1 (en) 2000-01-28 2005-11-30 Statens Serum Institut Methods to identify ctl epitopes of hiv
NO314587B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
WO2002028165A2 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
JP2004535369A (ja) * 2001-03-01 2004-11-25 アメリカ合衆国 試薬およびワクチンとして使用するための免疫原性ｈｉｖペプチド
RU2214274C2 (ru) 2001-08-16 2003-10-20 Государственное предприятие Институт иммунологии Федерального управления медико-биологических экстремальных проблем при МЗ РФ Иммуногенная композиция, содержащая химерный полипептид вич, полипептиды и тест-система для обнаружения антител к вич
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
US20040001845A1 (en) 2002-05-20 2004-01-01 Marcus Altfeld Cytotoxic T-cell epitopes of HIV-1 virus
EP1578432A4 (en) 2002-10-03 2008-07-30 Epimmune Inc HLA BINDING PEPTIDES AND USES THEREOF
CA2520768A1 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
CN102010463A (zh) * 2003-09-17 2011-04-13 杜克大学 共有/祖先免疫原
DK1778282T3 (en) * 2004-08-17 2016-06-06 Roussy Inst Gustave Mutated HIV NEF TO MODULATION OF IMMUNITY
CA2620874A1 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000049038A2 (de) * 1999-02-19 2000-08-24 Ulrich Schubert Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung
WO2003015702A2 (en) * 2001-08-16 2003-02-27 The General Hospital Corporation Epitopes of human immunodeficiency virus-1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAKAPPAGARI N. K. ET AL.: "Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-Astar 201 mice" *

Also Published As

Publication number Publication date
PL2392587T3 (pl) 2016-08-31
JP6422698B2 (ja) 2018-11-14
AP2015008680A0 (en) 2015-08-31
EP2004676B1 (en) 2016-11-16
IL193965A0 (en) 2011-08-01
BRPI0708708A2 (pt) 2011-06-07
CN104558126A (zh) 2015-04-29
JP2009529570A (ja) 2009-08-20
DK2392587T3 (en) 2016-05-23
SG170092A1 (en) 2011-04-29
KR20080106467A (ko) 2008-12-05
US20150182618A1 (en) 2015-07-02
US20170281750A1 (en) 2017-10-05
EP2004676A2 (en) 2008-12-24
US9675686B2 (en) 2017-06-13
US20100055119A1 (en) 2010-03-04
WO2007104932A2 (en) 2007-09-20
EA019733B1 (ru) 2014-05-30
UA97800C2 (uk) 2012-03-26
US8992934B2 (en) 2015-03-31
US10034933B2 (en) 2018-07-31
CN102443052A (zh) 2012-05-09
ES2616341T3 (es) 2017-06-12
AP2008004609A0 (en) 2008-10-31
MX2008011520A (es) 2009-01-07
NO20083576L (no) 2008-12-10
AU2007226430B2 (en) 2013-08-29
EA200870342A1 (ru) 2009-02-27
IL219544A0 (en) 2012-06-28
NZ570708A (en) 2011-12-22
HK1171027A1 (en) 2013-03-15
AU2007226430A1 (en) 2007-09-20
AU2007226430A2 (en) 2008-10-09
JP2015007069A (ja) 2015-01-15
EP2392587A1 (en) 2011-12-07
CN102443052B (zh) 2014-12-31
ES2573105T3 (es) 2016-06-06
US20130039937A1 (en) 2013-02-14
EP2392587B1 (en) 2016-05-04
CN104558126B (zh) 2020-02-14
CA2645342A1 (en) 2007-09-20
DK2004676T3 (en) 2017-02-20
WO2007104932A3 (en) 2007-11-22
JP2013040172A (ja) 2013-02-28

Similar Documents

Publication Publication Date Title
IL211762A0 (en) Pegylated opiods, compositions comprising the same and uses thereof
IL195580A (en) L – fkbp polypeptides, preparations containing them, methods of preparation and use
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
EP2039366A4 (en) COMPOSITION CONTAINING PEPTIDE AS ACTIVE INGREDIENT
IL210589A0 (en) The tuberculosis rv2386c protein, compositions and uses thereof
IL197061A (en) Compounds that inhibit the interaction of bcl proteins with binding partners, their medicinal products and their use
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
IL215603A0 (en) Human protein scaffold with controlled serum pharmacokinetics, compositions comprising the same and uses thereof
IL198248A0 (en) Hepatitis c virus inhibitors and compositions comprising the same
PL1913138T3 (pl) Sposoby wytwarzania pankreatyny w proszku o niskiej zawartości wirusa
IL205705A0 (en) Anti-influenza antibodies, compositions comprising the same and uses thereof
IL197923A (en) Synthetic peptides, pharmaceutical preparations containing them and their uses
IL197924A (en) Synthetic peptides, pharmaceutical preparations containing them and their uses
IL213043A0 (en) Lantibiotic carboxyamide derivatives, compositions comprising the same and uses thereof
IL185308A0 (en) Replikin peptides and uses thereof
EP1976864A4 (en) NEW PEPTIDE AND ITS USE
IL195525A0 (en) Replikin peptides and uses thereof
IL192824A (en) Peptide compounds, pharmaceuticals containing them and their use
IL213026A0 (en) TNA-a INHIBITING PEPTIDES, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF
GB0615635D0 (en) Immunogenic proteins and uses thereof
IL219544A0 (en) Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
AP2008004512A0 (en) Bacteriocion inducer peptides
ZA201006443B (en) Novel immunoregularory peptides,compositions and uses thereof
IL207174A0 (en) Peptides, compositions, and uses thereof
GB0704352D0 (en) "Peptide, compositions and uses thereof"